Bioinformatics CRO Podcast · Jul 2025
Podcast episode with Elizabeth Ruzzo on precision medicine for personalized birth control and adyn’s mission to make scientific discovery more inclusive.
The first test designed to prevent birth control side effects
Company research
Public company, workplace, funding, and market signals
Overview
adyn is a remote-first precision medicine / digital health startup focused on helping people choose birth control with less trial-and-error by combining at-home DNA and hormone testing, medical history, and telehealth prescribing. Public profiles place the company in Seattle, with a distributed team and a consumer test priced at $369.
Primary product
The Birth Control Test — an at-home, DNA-and-hormone-based test that provides personalized birth control recommendations plus virtual contraceptive counseling.
Founded
2019
Headquarters
Seattle, United States
Team size
1-10
Work style
Remote
Industry
Biotechnology Research
Sub-industry
Precision medicine / women’s health / digital health
Offices
Seattle, Washington, United States
Claymont, Delaware, United States
London, United Kingdom
Business model
direct-to-consumer diagnostic testing
telehealth / virtual care
mail-order prescription delivery
physician / prescriber partnerships
Funding
Stage
Seed
Total raised
$2.6M
Latest round
Seed · Apr 2021
Latest amount
$2.5M
People & investors
Work & culture
Mission-driven, data-driven, scientifically rebellious, thoughtful, inclusive, proactive, and collaborative; explicitly centered on closing the medical research gender gap.
Work style
Remote
Compensation
Adyn says compensation is equitable and that salary negotiation is eliminated to help bridge pay gaps; no public salary bands were found.
Benefits
100% coverage of healthcare premiums
100% coverage of dental premiums
100% coverage of vision premiums
exercise stipend
workstation allowance
flexible self-scheduling
work from anywhere
Product & market
Pricing
Direct-to-consumer, one-time test purchase priced at $369; HSA/FSA accepted; insurance not accepted publicly.
Differentiators
- —Combines genetic analysis with hormone testing for contraceptive selection
- —At-home sample collection plus telehealth counseling
- —Evidence-based recommendations informed by CLIA/CAP lab processing
- —Designed to reduce birth-control side effects and trial-and-error prescribing
- —Inclusive framing that avoids narrowly defining the product as only a women's health service
Technology
Python
SQL
AWS
React
Aptible
Heroku
Nginx
MemberStack
Google Ads
Facebook Pixel
Google Data Studio
Varnish
Microsoft Excel
Customers
birth control users / patients seeking a better contraceptive match
physicians and prescribers
people who want to reduce birth-control side effects
Competitors
Nurx
The Pill Club
Clearblue
Elektra Health
Sehat Kahani
Mae
Meinian OneHealth
Scale & contact
Estimated revenue
under $1M (some third-party estimates are higher)
Estimated monthly visits
13.1K
Traffic estimate as of Jul 2026
Latest news
Inc. · Apr 2024
Inc. recognized Elizabeth Ruzzo of adyn on its 2024 Female Founders list, highlighting the company’s mission and the founder’s background in genomics and women’s health.
Femtech Insider · Apr 2024
A fireside-chat writeup featuring Elizabeth Ruzzo discussing adyn’s birth-control-focused precision medicine approach and the broader women’s health funding environment.
GlobeNewswire / adyn · May 2022
Official launch announcement for The Birth Control Test, including the product’s nationwide availability (with state exclusions) and $369 price point.
GeekWire · Apr 2021
Coverage of adyn’s $2.5M seed round, including co-leads Lux Capital and M13 and participation from Y Combinator, Ascend VC, Madrona Pioneer Fund, and angel investors.
Jobs and careers at adyn
0 jobs at adyn
No open positions
Check back later for new openings